Efficacy and safety of fixed-dose combination therapy with gemigliptin (50 mg) and rosuvastatin compared with monotherapy in patients with type 2 diabetes and dyslipidaemia (BALANCE): A multicentre, randomized, double-blind, controlled, phase 3 trial.
Ji Cheol BaeKyung Wan MinYong Hyun KimKyoung-Ah KimEun-Gyoung HongCheol-Young ParkSong HanBong Soo ChaPublished in: Diabetes, obesity & metabolism (2018)
The FDC of gemigliptin and rosuvastatin is safe and is effective in reducing both blood glucose and LDL-C levels; thus, it could be a good therapeutic choice for type 2 diabetic patients with dyslipidaemia.